For Adult Consumers Who Smoke
- If you currently smoke and are considering switching, JUUL2 is now an FDA-authorized option — talk to your healthcare provider about whether it's right for you
- Understand that the FDA's authorization is based on complete switching, not dual use
- Look for the JUUL2's age-verification features: the device pairs with a 21+ app and includes a Pod ID chip to prevent counterfeit pod use
- Check whether your state allows the sale of menthol-flavored e-cigarettes — states like California and Massachusetts have statewide flavor bans that may restrict availability
- Compare JUUL2's 18 mg/mL nicotine strength against your current smoking habits to gauge whether it addresses your nicotine needs
For Retailers
- Verify that JUUL2 products appear on your state's vapor product directory or PMTA registry before stocking — this is separate from FDA authorization
- Check state flavor ban laws: if your state bans menthol e-cigarettes (e.g., California, Massachusetts, New Jersey, New York, Rhode Island), JUUL2 menthol pods cannot be sold regardless of FDA authorization
- Update your inventory management system to track the new JUUL2 SKUs separately from original JUUL products
- Ensure all staff understand that "FDA-authorized" does not override state-level restrictions — compliance is layered
- If you sell nicotine pouches in New York, prepare for the 75% wholesale tax that took effect September 1, 2026, including the floor tax filing due by September 21
For Manufacturers and Industry Professionals
- Study the FDA's benefit-risk reasoning for menthol — the explicit weighing of adult switching rates against youth appeal sets a framework for future flavor applications
- Note that FDA's PMTA backlog has been reduced by approximately 70% during 2025, with review times accelerating — now may be the time to file
- Consider incorporating age-verification and access-control technologies (like JUUL2's Pod ID and device lock) as risk-mitigation evidence in your own PMTA submissions
- Track the 9 e-cigarette products authorized in 2026 (1 Glas in March, 4 Glas in May, 3 JUUL2 in August) to identify which product categories FDA is prioritizing
- Monitor state directory requirements — products may need state-by-state certification beyond federal authorization
